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Abbreviations 
 
cDNA  complementary DNA 
CETSA  cellular thermal shift assay 
CRISPR clustered regularly interspaced short palindromic repeats 
DARTS  Drug affinity response target stability 
dsRNA  double-stranded RNA 
ESI  electrospray ionisation 
HIV  human immunodeficiency virus 
ICAT  isotope-coded affinity tagging 
IEX  ion exchange 
iTRAQ  isobaric tags for relative and absolute quantitation 
LC  liquid chromatography 
LC-MS  liquid chromatography – mass spectrometry 
LC-MS/MS liquid chromatography – tandem mass spectrometry 
MALDI  matrix-assisted laser desorption ionisation 
MOA  mode of action 
mRNA  messenger RNA 
MS  mass spectrometry 
MS/MS  tandem mass spectrometry 
PCR  polymerase chain reaction 
qPCR  quantitative polymerase chain reaction 
RNAi  RNA interference 
RT-qPCR reverse transcription – quantitative polymerase chain reaction 
SDS-PAGE sodium dodecyl sulphate – polyacrylamide gel electrophoresis  
SILAC  stable isotope labelling with amino acids in cell culture 
sgRNA  single guide RNA 
SRM  selected reaction monitoring 
TICC  target identification by chromatographic co-elution 
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Abstract 
 
Phenotypic assays are becoming increasingly more common among drug discovery practices, 
expanding drug target diversity as lead compounds identified through such screens are not limited to 
known targets.  While increasing diversity is beneficial to the drug discovery process and the fight 
against disease, the unknown modes of action of new lead compounds can hamper drug discovery as, 
in most cases, the process of lead compound optimisation is made difficult due to the unknown nature 
of the target; blindly changing substituents can prove fruitless due to the inexhaustible number of 
potential combinations, and it is therefore desirable to rapidly identify the targets of lead compounds 
developed through phenotypic screening.  In addition, leads identified through target-based screening 
often have off-target effects that contribute towards drug toxicity, and by identifying those secondary 
targets the drugs can be improved.  However, the identification of a leads mode of action is far from 
trivial and now represents a major bottleneck in the drug discovery pipeline.  This review looks at 
some of the recent developments in the identification of drug modes of action, focusing on phenotype-
based methods using metabolomics, proteomics, transcriptomics and genomics to detect changes in 
phenotype in response to the presence of the drug, and affinity-based methods using 
modified/unmodified drug as bait to capture and identify targets. 
 
Introduction 
 
Paul Ehrlich is widely regarded as the founder of modern drug discovery through his conception of 
chemotherapy – the use of a single molecule “magic bullet” with pathogen-specific binding to 
selectively kill a pathogen but not the host (1,2).  By screening a library of small synthetic compounds 
against parasite-infected rodents (the process of phenotypic screening, or phenotype-based drug 
discovery), he identified compounds that were active against the parasites, then improved compound 
potency and selectivity (the process of lead optimisation) by adding substituents, and in 1907 
produced Salvarsan, the first synthetic drug created by structure-based drug discovery (3). 
 
Phenotype-based drug discovery remained the principle method of identifying new lead compounds 
until advances in molecular biology and genomics in the 1980s (namely PCR (4,5), nucleotide 
sequencing (6,7) and recombinant protein biology) and technological development (high-throughput 
chemical synthesis and high-throughput screening) allowed the switch to target-based drug discovery 
(8).  This process involves the screening of compound libraries against purified recombinant target 
protein, typically targeting proteins with key roles in disease pathogenesis or proteins specific to the 
disease of interest (several reviews detailing and comparing phenotype- and target-based drug 
discovery methodologies are available (9–12) so will not be discussed herein).  While there have 
undoubtedly been a large number of successes from target-based methods (11,13), attrition rates are 
high as lead compounds identified and optimised in vitro often fail in subsequent cell-based trials due 
to a range of issues including poor cell uptake, preferential off-target binding; unexpected toxicity in 
host cells; or even non-essentiality of the target (8).  Risk of encountering some of these shortcomings 
can be minimised by restricting targets to those known to be essential and druggable, eliminating 
known and likely toxins from chemical libraries, and by restricting chemical libraries to compounds that 
are “drug-like”.  As such, drug targets in target-based methods are limited to those believed to be good 
and which can be expressed, purified and assayed, and therefore exclude the majority of exploitable 
targets from development; there are an estimated 600-1500 exploitable human targets (14), yet 
several analyses indicate that <700 of them are targeted by the ~2000 unique therapeutically active 
drugs currently approved for use in Western medicine (13,15). In addition, it is becoming ever more 
apparent that many drugs have complex modes of action, with primary and secondary targets of 
differing affinities and it may not be possible to anticipate such secondary effects from target-based 
screening practises. 
 
Technological developments in high throughput screening, availability of chemical libraries and the 
availability/culturability of infectious organisms and cell lines as models for numerous human diseases, 
coupled with the shortcomings of target-based drug discovery have led to a resurgence in phenotypic 
screening both within academia and the pharmaceutical industry (11).  As phenotypic screening does 
not focus upon any particular target directly, it removes target-bias and potentially expands the target 
repertoire by allowing the identification of new lead compounds with unknown targets and those 
previously thought undruggable.  Furthermore, it allows the testing of drug combinations (i.e., drug 
pairs which have different targets) in their biological context and is proving effective in the fight against 
viruses (for example, HIV, (16)) and cancers (17–19).  However, a major drawback of phenotypic 
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screening is that much of the time the target(s) and mode of action (MOA) of the newly developed 
drug are unknown, making the drug difficult to further optimise for potency and selectivity, and as a 
consequence target identification through drug MOA studies represents a major bottleneck in the drug 
discovery pipeline.  Investigations of drug modes of action are not limited to studies following lead 
compound identification by phenotypic screening; lead compounds identified through target-based 
screening seldom bind solely to the target screened against and it is prudent to identify additional 
interacting proteins (which may include desirable secondary targets, undesirable off-targets or 
highlight drug uptake receptors/systems) to help improve compound efficacy/selectivity.  Furthermore, 
by identifying the undesirable off-targets, lead compounds that would normally be rejected can instead 
be modified to reduce their off-target affinities, thereby reducing the high attrition rate that currently 
plagues drug discovery.  A number of methodologies have recently been developed to help identify 
targets of drugs and drug modes of action, including direct/affinity-based methods that show the 
physical interaction between drugs and their targets, and indirect/phenotypic-based methods that 
show drug-induced changes in phenotype from which targets and modes of action can be inferred.  
Herein we review recent advances in drug MOA methodologies that can be applied to identify protein 
targets of newly-identified (or pre-existing) drugs using examples from different areas of drug 
discovery research. 
 
Indirect / phenotype-based methods 
 
A drugs mode of action can often be determined by comparing the phenotype of drug-treated cells 
with untreated cells.  In some cases, the number of potential drug targets leading to the given 
phenotype may be relatively small and a focused analysis on those potential targets is likely suitable.  
However, in most cases the number of potential targets leading to the phenotype, such as cell death, 
is potentially enormous and global analyses are required to determine the drug targets.  Some 
approaches investigate the acute effects of drug treatment to determine what happens to cells as they 
progress towards the end phenotype, while others investigate how cells adapt to chronic drug 
treatment and develop resistance mechanisms.  Physical changes that occur during a cell-cycle or in 
cell morphology can sometimes indicate a drugs mode of action, but often the morphological change 
is too subtle or non-descript, and one needs to look at phenotypic changes at the molecular level.  
Over the past decades, advancements in the “omics” fields – genomics, transcriptomics, proteomics 
and metabolomics – have led to the generation of cost-effective, high throughput methodologies to 
analyse and compare molecular systems at an unprecedented scale.  While they have been used 
primarily to characterise and understand disease, they can also allow analysts to determine how drugs 
work at the molecular level. 
 
Genomics 
 
The post-genomic era has significantly advanced/enhanced the drug discovery process, and large-
scale genomic studies can be incorporated into techniques for drug target identification.  The creation 
of organisms resistant to a candidate drug can be an effective method to identify specific drug targets 
(Fig 1A).  For example, one study identified leucyl-tRNA synthetase as the target of antifungal 
tavaborole by culturing Saccharomyces cerevisiae in the presence of the drug to generate 
spontaneous resistance mutants, whose DNA was digested into 4-10 kb fragments, inserted into a 
yeast vector, and screened for the ability to protect tavaborole-susceptible cells by tavaborole 
selection (20).  Sequencing of vector inserts from the small number of surviving colonies revealed that 
all contained mutations in leucyl-tRNA synthetase, which prevented the drug from binding.  Advances 
in nucleotide sequencing technology allowed a similar technique to be applied by Ioerger and 
colleagues, who identified targets of several antibacterials in Mycobacterium tuberculosis, except 
entire genomes of resistant mutants were sequenced and aligned to genome sequences of the 
parental strain to detect deletions or resistance-associated polymorphisms (21).  In this study the 
authors detected mutations in direct drug targets, transcription factors regulating the targets, and a 
pro-drug activator, demonstrating that this technique can not only identify targets in an unbiased 
manner, but also highlight potential resistance mechanisms, which may be of added value as it can 
guide the development of combination therapies to prevent the emergence of resistance in the field.  
 
Genomic screens are limited to cells that spontaneously develop resistance, and to circumvent this, 
the Horn laboratory has applied genome-wide RNA interference (RNAi) libraries to identify proteins 
targeted by drugs or associated with resistance in Trypanosoma brucei (22–25), the parasite 
responsible for African sleeping sickness (Fig 1B).  By transforming parasites with tetracycline-
UBMB Life 2017 DOI: 10.1002/iub.1697  Author Accepted version 4 
inducible expression plasmids containing fragments of sheared T. brucei genomic DNA, they 
generated a library of cells, each expressing a random dsRNA to silence the expression of an 
individual gene, so that the entire genome could be knocked down in a mixed population of cells.  The 
addition of sub-lethal drug concentrations then allowed parasites expressing irrelevant RNAi 
sequences to survive, while those expressing RNAi to proteins targeted by the drug were sensitised 
and killed, and those expressing RNAi to proteins involved in drug uptake thrived as less drug was 
taken up.  Sequencing of RNAi species remaining using high throughput sequencing technology 
indicated which category each silenced gene fell into, implicating several proteins in drug uptake and 
drug activity.  A complementary approach was used by Begolo et al (26), who developed an 
overexpression library in T. brucei by inserting genome fragments into ectopic expression vectors, 
providing cells with resistance to difluoromethylornithine and DDD85646 when overexpressing their 
 
 
 
 
 
Fig 1.  Genomics methods for target identification. 
    A) Sequencing of resistant strains.  Cells can adapt over time to overcome selective pressure from drugs 
(symbolised by the mutation of one or more genes, i.e. from blue to red). Genome-wide deep sequencing of 
resistant strains can reveal which genes have mutated to highlight potential targets of the drug, as well as indicate 
proteins that may be involved in drug uptake, trafficking and/or metabolism. 
    B) Genome-wide RNAi (underexpression).  A genome-wide RNAi library can be generated by digesting an 
entire genome and inserting small DNA fragments with < 1 gene into RNAi expression plasmids.  Transfection of 
the library into cells results in knock-down expression of a single gene in each cell.  Cells expressing the RNAi for 
a given drug target (in this example, yellow) will be sensitised to the drug and killed at normally sub-lethal drug 
concentrations, removing that RNAi from the library.  Sequencing the RNAi of surviving clones can reveal the 
drugs target by its absence from the drug-treated culture. 
    C) Genome-wide overexpression.  Similar to RNAi, except gene products are expressed to overexpress one 
protein or protein fragment per cell.  Cells overexpressing a given drug target will be desensitised to the drug and 
will survive normally lethal drug concentrations.  Sequencing the overexpressed gene of surviving clones will 
reveal the drugs target and genes associated with resistance. 
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targets, ornithine decarboxylase and N-myristoyltransferase respectively (Fig 1C), and together, these 
genome-wide knockdown/in techniques replicate the effects of classical reverse genetics in a high-
throughput manner. 
 
Not all organisms are amenable to RNAi, and the recent discovery of the CRISPR/Cas9 system, and 
its subsequent use in a wide range of organisms to study loss-of-function (reviewed in (27)), may 
replace the use of RNAi screens in future drug target identification efforts.  Cas9 is a bacterial DNA 
repair endonuclease which, when expressed in eukaryotic cells, introduces double strand breaks in 
DNA matching the sequence of single guide RNA (sgRNA) templates.  Endogenous DNA double-
strand break repair pathways then repair the damage using a DNA template, and it is therefore 
possible to knockout individual genes in Cas9-transfected cells using DNA templates with frameshift 
deletions.  Shalem and co-workers generated a library of A375 human melanoma cells in which 
>18,000 genes were singly knocked out, and they identified several genes involved in resistance to 
the BRAF protein kinase inhibitor vemurafenib following vemurafenib-selection (28).  Another study 
has engineered Cas9 to act as a sgRNA-mediated DNA-binding protein to upregulate specific gene 
expression (29), and it is likely that this system will be valuable for drug target identification in 
eukaryotic overexpression libraries in the future. 
 
Transcriptomics 
 
While genomic approaches typically elude to chronic effects (genomic adaptions) of drug treatment, 
transcriptomics (several methodologies of which are reviewed in (30)) can be used to determine both 
chronic and acute effects, as the transcriptome contains genomic sequence data, but at levels that 
dynamically reflect the needs of the cell, and which change in response to drug treatment.  Burczynski 
and co-workers analysed the effects of 100 drugs and toxic compounds on this latter aspect of 
transcriptomics by quantifying transcript levels in drug/compound-treated HepG2 cells using DNA 
microarrays (31).  Following drug/compound treatment, they reverse-transcribed mRNA transcripts to 
Cy3/Cy5-fluorescently labelled complementary DNA (cDNA), which was subsequently hybridised to 
prefabricated chips containing arrays of DNA sequences covering 250 human genes, and quantified 
relative transcript abundance by fluorescence imaging (Fig 2B).  They reported that compounds with 
similar modes of action had similar gene expression signatures, for example, DNA-damaging drugs 
such as cisplatin induced expression of DNA repair proteins, and microarrays have subsequently been 
used extensively for drug mode of action and toxicology investigations.  Despite their widespread use, 
a major limitation of microarrays is that target sequences must be known and prefabricated on the 
chips, so unknown sequences cannot be detected.  This may appear trivial as the number of 
organisms that have been genome-sequenced increases and the number of unknown sequences 
correspondingly decreases, but it means that mutations that occur in response to drug treatment may 
be missed.  In addition, the analogue nature of the signal (emitted fluorescent light) makes it difficult to 
confidently detect and quantify low abundance species. 
 
The development of next-generation sequencing that has facilitated genome-wide sequencing has 
also transformed transcriptomics, as direct sequencing of cDNA transcripts (RNA-seq) allows their 
simultaneous identification and binary quantitation (Fig 2C).  Mortazavi and co-workers mapped and 
quantified the transcriptomes of three distinct mouse tissues by sequencing and scoring >40 million 
cDNA fragments per tissue and aligning each to a reference genome to determine the gene from 
which they were transcribed (32).  In total they detected expression of >11000 genes to high certainty, 
~5000 of which were expressed in a tissue-specific manner and included genes known to be 
specifically expressed in each of them.  In addition, they detected splice variants for ~3500 genes, and 
RNA-seq should therefore be ideal for the analysis of the acute effects of drug treatments in cells.  To 
assess the chronic effects of drug treatment, Wacker et al deep sequenced cDNA transcripts from 
human HTC-116 cell clones made resistant to BI2536, a Polo-like kinase 1 inhibitor, and detected two 
point mutations in the BI2536-binding site of Polo-like kinase 1 (33).  Although their approach was 
similar the genome sequencing of drug resistant cells by Ioerger (21), non-coding introns, which are 
removed during mRNA splicing, are not sequenced during RNA-seq, making it more cost-effective 
than genome-wide sequencing. 
 
Once differences between expression levels in particular genes have been ascertained, they can be 
verified using reverse transcriptase coupled with quantitative PCR (RT-qPCR, Fig 2D), which involves 
the amplification of specific transcript cDNAs with primers specific to the gene of interest and then 
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Fig 2.  Transcriptomics methods for target identification. 
    A) Reverse transcription.  To quantify the number of mRNA transcripts mRNA is first reverse transcribed to 
cDNA, which is more stable and amenable to downstream applications.  In this example, the drug causes a 
decrease in expression of transcript 1 and an increase in transcript 4 expression. 
    B) Dual-colour DNA microarray.  cDNA is labelled with a sample-specific fluorescent probe and then 
hybridised to an array of prefabricated gene sequences.  Relative fluorescence shows which sequences are 
present in each sample and their relative abundances.  A disadvantage is that sequences that are not on the chip 
cannot be detected.  
    C) RNA-seq. cDNA is restriction-digested and tagged with sample-specific octameric sequences (shown as 
green/red).  All fragments are simultaneously sequenced using next-generation sequencing to provide accurate 
quantitation and information on splice variation and generation of single nucleotide polymorphisms. 
    D) Reverse transcription quantitative-PCR (RT-qPCR).  Primers specific to the transcripts of interest are 
used to amplify those cDNA.  The use of fluorescent probes in TaqMan assays quantifies the relative number of 
amplicons to accurately show the relative abundance of each transcript in the sample.  Impractical for 
transcriptome-wide analyses, but ideal for following up hits. 
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quantifying the amount of cDNA amplified (34).  Different methods have been reported for transcript 
cDNA quantitation, but the gold standard is the TaqMan real-time assay (35), which requires the 
addition of a short transcript-specific probe labelled with a fluorophore at one end and quencher at the 
other.  The quencher absorbs the energy emitted by the fluorophores when in close proximity in the 
intact probe (through Förster resonance energy transfer), either in free solution or bound to the target 
cDNA, but as the Taq polymerase elongates the unlabelled primer, it degrades the labelled probe 
bound to the target allowing the released fluorophore to emit light.  The fluorescence is measured after 
every PCR cycle and the increase in fluorescence is proportional to the amount of amplicon 
synthesised, resulting in an accurate quantitation of target transcript. 
 
Proteomics 
 
As mRNA transcripts are translated into proteins, the effects that drugs have on a cells transcriptome 
may be reflected in the cells proteome, and can be determined by liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) and peptide mass fingerprinting (36–38).  In shotgun mass 
fingerprinting, which is the most widely-used form of proteomics, proteins from a complex mixture 
(such as an entire protein extract from cells) are enzymatically digested and peptides are separated 
and analysed by data-dependent acquisition, whereby parent ions (peptides) are sampled and the 
most abundant species are fragmented to yield fragmentation ‘fingerprints’ from which parent ions can 
e sequenced (Fig 3A).  Sequences are then assigned to proteins when compared against a reference 
database by the MASCOT software (39), and relative protein abundance determined from the number 
of reads obtained.  While genome-wide and transcriptome sequencing analyses allow the identification 
of new (mutated) sequences in response to drug adaption by aligning the sequences against genomic 
templates, no such application currently exists for proteomic analyses; peptides containing single or 
multiple mutations that are not in the reference database will not be assigned to a protein, so peptide 
mass fingerprinting cannot readily identify drug targets from the generation of mutant proteins.  
However, peptide mass fingerprinting is ideal for detecting changes in protein expression levels or in 
their post-translational modifications.  It is possible to analyse drug-treated and untreated samples 
separately, however, their direct quantitative comparison by shotgun proteomics is difficult due to the 
somewhat inconsistent nature of data-dependent acquisition, and it is often preferable to differentially 
label proteins, during or after drug treatment, from each sample and subsequently analyse them 
simultaneously to reduce sampling variation – reviewed by Steen and Pandey (40).  For example, Oda 
and colleagues used stable isotope labelling with amino acids in cell culture (SILAC (41)) to label 
proteins from one sample by growing cells in medium supplemented with heavy (15N-labelled) amino 
acids, while cells from a second sample were grown in unlabelled medium.  Proteins incorporating the 
heavy amino acid were characteristically heavier than those from cells in unlabelled medium, 
differentiating the proteins from the different samples and allowing their relative quantitation.  Similar 
techniques have been used to label proteins from primary cells, which often cannot be cultured for 
sufficient time to allow for SILAC.  For example, isotope-coded affinity tagging (ICAT, (42)) involves 
chemically adding differential tags to cysteine residues immediately prior to LC-MS/MS so that it can 
be determined from which sample each Cys-containing peptide came from.  Alternatively, isobaric 
tags for relative and absolute quantitation (iTRAQ, (43)) labels primary amines with differential tags, 
allowing every peptide to be allocated to a sample, and was the method utilised by Yang et al to 
determine the mode of action of a bactericidal houttuyfonate by dissecting the global protein 
alterations in Streptococcus pneumoniae in response to the compound (44).  Recently SWATH-MS 
(45) has been developed as a data-independent alternative to shotgun peptide mass fingerprinting 
and overcomes some of the limitations of data-dependent acquisition.  Rather than sampling parent 
ions and fragmenting the most abundant species, SWATH-MS fragments every parent ion over a 
given m/z range to more accurately and reproducibly count ions, allowing the label-free comparison of 
different samples from separate analyses. 
 
A targeted approach often follows the ‘global’ analysis, and proteins of interest can be enriched to 
detect low-abundance species.  For example, Pandy et al identified several targets of the epidermal 
growth factor receptor, which phosphorylates target tyrosine residues following receptor activation, by 
enriching tyrosine-phosphorylated proteins with an anti-phosphotyrosine antibody and analysing 
captured proteins by MS/MS (46).  Using a similar technique, Pan et al determined the effects of 
U0126 and SB202190, two mitogen-activated protein kinase inhibitors, on the phosphoproteome of 
cancer cells by capturing phosphoproteins through titanium oxide affinity chromatography coupled with 
MS/MS (47). 
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Fig 3.  Mass spectrometry methods for target identification. 
    A) Proteomics and peptide mass fingerprinting using SILAC.  Continuing the example from Fig 3, the drug 
causes a decrease in expression of protein 1 and an increase in protein 4 expression.  In addition, it inhibits the 
phosphorylation (orange oval) of protein 3.  Proteins from untreated cells are unlabelled (green), while proteins 
from drug-treated cell grown in 15N-labelled medium are heavy (red).  Proteins are digested and peptides 
analysed by LC-Ms/MS.  The first round of MS detects the mass and abundance of each parent ion (peptide).  As 
light and heavy peptides differ slightly in mass, their relative abundance from each sample can be determined.  
Subsequent fragmentation of a selected parent ion at a peptide bond yields a unique peptide mass fingerprint 
from which the sequence and posttranslational modifications can be determined, allowing peptides to be assigned 
to proteins for quantitation. 
    B) Metabolomics.  Schematic representation of two metabolic pathways showing metabolic flux.  The  size of 
the arrows represents the rate of flux in untreated (green arrows) and drug-treated (red arrows) cells.  In this 
example the drug inhibits the conversion of oxalic acid to pyruvate, decreasing the amount of pyruvate and lactate 
produced, and excess oxalic acid is instead metabolised through an alternative route to glutamic acid and 
glutamine.  Relative metabolite concentrations can be determined by MS, and a comparison between untreated 
and drug-treated can reveal which metabolites change.  Subsequent fragmentation of a selected parent ion 
reveals a metabolites fingerprint from which the relative quantities of isomers can be determined. 
 
UBMB Life 2017 DOI: 10.1002/iub.1697  Author Accepted version 9 
Changes in protein abundance or posttranslational modification need to be verified, and western 
blotting provides a simple means to do this.  Western blotting can readily be applied to show 
differences in protein levels or posttranslational modification using primary antibodies raised against 
the target, while dual colour scanning of blots using secondary antibodies conjugated to near far-red 
fluorophores (700 nm and 800 nm) allows test and control samples to be analysed simultaneously. 
 
Metabolomics  
 
Drugs that inhibit metabolic enzymes may cause accumulation of their substrates and depletion of 
their products (Fig 3B), so it is possible to determine a drugs target by detecting metabolomic changes 
in response to drug treatment.  It is often desirable first to compare the ‘global’ metabolomes of drug-
treated and untreated cells in an untargeted, unbiased manner.  Mass spectrometry (MS) methods, 
such as electrospray ionisation (ESI, (48)) or matrix-assisted laser desorption ionisation (MALDI, (49)), 
are ideally suited to the comparative untargeted analysis of entire metabolomes from whole cell 
extracts as, depending on the device and sensitivity used, MS can differentiate molecules differing by 
a single electron and it is therefore theoretically possible to determine the precise chemical makeup of 
virtually every mass peak detected, assign each to a metabolite from a mass library, and quantify the 
relative abundance of each chemical entity based on peak intensity.  However, the inability to 
distinguish different metabolites with the same chemical formulae (isomers) makes MS alone 
unpractical for comparative metabolomics.  Tandem mass spectrometry (MS/MS) can resolve this by 
fragmenting sample ions of interest (precursor or parent ions) into product or daughter ions, with each 
molecule yielding a unique fragment fingerprint which can be used to identify the isomers present and 
their relative abundance.  To assist in metabolite identification, the METLIN metabolomics database 
(50,51) and Human Metabolome Database, HMDB (52), provide comprehensive libraries, with 
excellent online tools for querying MS/MS data.  Alternatively, liquid chromatography (LC) can be used 
to separate samples into compound classes prior to MS, and LC-MS has been used to identify the 
effects of miltefosine on lipid metabolism in Leishmania (53) and for mechanistic investigations of 
several antiprotozoal drugs (54).  While the application of LC offers great selectivity for the separation 
of biomolecules/drugs, it should be highlighted that an MS compatible solvent system is required and 
can reduce separation efficacy.  Additionally, a higher sample concentration is required to mitigate 
chromatographic losses, resulting in an overall compromise in sensitivity compared to MS alone.  
Further detail on the applications of LC-MS in drug development can be found in reviews by Lee (55) 
and Lu (56), while considerations for untargeted metabolomics generally are detailed extensively by 
Dunn (57) and Patti (58).   
 
Once an untargeted, global approach has identified a metabolic area that appears affected by 
treatment with a drug of unknown mode of action, a targeted approach can be used to focus the 
investigation and gain sensitivity and/or certainty that the changes detected are in the metabolites 
presumed (reviewed in (59)).  One method is to reduce sample complexity by extracting the relevant 
metabolite species for analysis, such as a lipid extract for lipidomics (returning to the miltefosine mode 
of action as example (53)), rather than analysing the whole cell extract.  An alternative approach is to 
use selected reaction monitoring (SRM) methods, whereby the mass spectrometer is set to only select 
and record specific precursor/product ion combinations from the unfractionated complex mixture, 
greatly increasing detection sensitivity as the majority of a sample can then be rejected and ignored.  
The use of stable isotope-labelled (commonly deuterium, 15N or 13C) metabolites can also be highly 
informative in focused analyses, as they allow the analyst to follow metabolic flux from a given 
metabolite (60,61) and verify changes detected in global analyses. 
 
Matrix combination screening 
 
Combination therapies are gaining momentum as an efficient means of tackling disease.  Indications 
that can rapidly adapt to selective pressure, such as HIV and cancer, can quickly overcome 
monotherapies, but by combining drugs that have different targets or mechanisms of action, the 
number of resistance mutations required to gain selective advantage are increased (16).   Drug 
combinations can also be used to reduce toxic side effects by allowing lower concentrations of toxic 
drugs to be used where they work synergistically.  High throughput matrix combination screening is 
now being used to identify suitable drug combinations for cancer (17–19) and malaria (62), whereby 
cell viability assays are carried out with drug pairs in perpendicular serial dilution checkerboards using 
384-well or 1536-well tissue culture plates.  Such checkerboards can show whether drug pairs 
synergise (for example by targeting different targets in parallel pathways), antagonise (by hitting 
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different targets in the same pathway) or work additively (by targeting the same or unrelated targets).  
By screening a drug of unknown action with drugs of known action the analyst can build an interaction 
network for the drug of unknown action to indicate how the drug works.  Drugs with the same modes 
of action typically have similar checkerboard profiles when tested pairwise with other drugs, so by 
comparing the checkerboard profiles of the unknown drug with those of known action it may be 
possible to determine its target.  High-throughput matrix combination screening is very much in its 
infancy and is likely to become a powerful tool in drug target identification, particularly as drug 
discovery shifts towards combination therapies generally to protect new discoveries from the 
emergence of resistance. 
 
Direct / affinity-based methods  
 
Affinity-based methods are able to demonstrate direct physical interaction between a drug and its 
target but usually require prior chemical modification of the drug. For example, the binding of 
radiolabelled or fluorescent drug analogues to their targets in native protein gels or microscopy can 
show the size and/or cellular localisation of their targets, while drug immobilised to a matrix can be 
used to capture targets (described in more detail below) for their identification by peptide 
fingerprinting.  However, the direct interaction between an unmodified drug and its target can also be 
detected by changing the stability or rigidity of the target through their physical interaction, and 
applications detecting these changes are also discussed. 
 
Direct interactions with modified drug 
 
Ideally a drugs target can be identified by peptide mass fingerprinting (36,37) following its direct and 
selective capture by the drug immobilised to a matrix using affinity chromatography (Fig 4A).  The 
principle of affinity chromatography was first demonstrated by Lerman in 1953 when a tyrosinase was 
partially purified from a crude mushroom extract through its binding to cellulose-immobilised p-
azophenol (a substrate-like inhibitor) and subsequent elution by mass action of competitive inhibitor in 
solution (63).  Since this pioneering work, affinity chromatography has been used extensively for target 
identification purposes.  A limitation of affinity chromatography is that target(s) seldom enrich alone as 
many proteins non-specifically bind to the matrix, so to address this Ong and colleagues combined 
affinity capture with SILAC to distinguish targets of several kinase inhibitors (64), including the broad-
spectrum kinase inhibitor K252a, from non-specific binders.  In one example they used one K252a-
bound matrix to capture 13C-labelled target proteins and another to capture unlabelled target proteins 
pre-incubated with competing soluble K252a, and analysed both eluates simultaneously by LC-
MS/MS.  They identified 48 potential targets (proteins absent from the control eluate), 46 of which 
were known kinases or kinase-associated proteins from a background of >500 non-specific 
contaminants (proteins present in the control eluate), demonstrating the sensitivity and selectivity of 
the procedure.  While the principle of affinity capture is simple, the process is not always trivial as the 
coupling of the inhibitor to the matrix may impede target-binding (either by the covalent attachment of 
a required binding atom, such as an H-bonding amide, directly to the matrix, or by steric hindrance 
from the matrix if the attached drug cannot reach into the targets binding cavity); the drug-target 
interaction may not be strong enough to retain the target while washing away non-targets; the target 
may not be sufficiently soluble (or solubilised) for it to wash on and off the matrix.  Many of these 
factors are reviewed by Rix and colleagues (65) so will not be discussed here. 
 
Inhibitors with only weak interactions with their targets (Ki >50 µM) may not be amenable to affinity 
chromatography directly, but photoaffinity labelling (reviewed by Smith and Collins (66)) can resolve 
this issue by covalently attaching a photoreactive analogue of the drug to its target (Fig 4B).  Suitable 
photoreactive substituents include azides, benzophenones and diazirines, which decompose under 
UV-irradiation to highly reactive nitrenes, diradicals or carbenes respectively, which then rapidly 
covalently bind to neighbouring molecules.  We recently developed bi-functional photoaffinity 
analogues of trypanocidal bis-tetrahydropyran 1,4-triazole compounds to identify their targets in T. 
brucei by attaching diazirine and alkyne moieties to our lead compound (67).  After employing a pulse-
chase methodology to traffic the bi-functional compound to its target in live cells, we photo-activated 
the diazirine to covalently conjugate the compound to its target in its biological context.  Subsequently 
we “clicked” on fluorescent Cy5.5-azide by copper-catalysed azide-alkyne cycloaddition (67,68) to 
microscopically visualise the cellular localisation of its target, and “clicked” on biotin-azide for target 
isolation by streptavidin affinity pull-down and target identification (68), utilising the ultra-high affinity of 
streptavidin for biotin (Kd <1 pM (69)).  The versatility of the alkyne moiety coupled with its small size 
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makes it an ideal chemical handle for such photoaffinity labelling techniques.  In addition, the alkyne, 
which is typically absent from biological tissue, can be used as a Raman label to visualise drug uptake 
in live cells by spontaneous Raman microscopy, which detects laser-induced vibrations of specific 
molecular functional groups (reviewed by Tipping and co-workers (70)). 
 
Direct interaction with unmodified drug 
 
The modification of a drug to show direct interaction with its targets is not always ideal as it may 
involve lengthy structure-activity-relationship analyses and time/skill synthesising analogues.  Several 
“label-free” methods have been employed to overcome these limitations and identify targets from 
complex protein mixtures using unmodified drugs.  Target identification by chromatographic co-elution 
(TICC) is one such method and involves detecting a change in the chromatographic retention time of a 
drug when it binds its target, and identifying the target by LC-MS/MS.  As proof of principle, Chan and 
colleagues demonstrated the methotrexate-dihydrofolate reductase interaction by TICC using non-
denaturing ion exchange chromatography (IEX) coupled with LC-MS in SRM mode to scan for the 
presence of methotrexate in IEX fractions (71).  They first performed IEX-LC-MS on methotrexate 
alone to determine the methotrexate retention time and suitable daughter ions to scan for, and then 
analysed methotrexate with purified dihydrofolate reductase and observed a shift in the retention time 
of methotrexate to that of dihydrofolate reductase, indicating that methotrexate was bound to the 
protein. Finally, they added methotrexate and dihydrofolate reductase to an E. coli cell lysate to 
represent a complex protein mixture.  Again, the retention time of methotrexate was different from 
unbound drug, and peptide fingerprinting of the relevant fraction confirmed that dihydrofolate 
reductase was present.  Chan and colleagues also demonstrated the drug-target interaction for 
several other drugs using the same procedure, demonstrating the general utility of this method for 
identifying drug targets. 
 
A drug-protein interaction can often change the thermostability of the protein by, for example, holding 
the protein in a more rigid conformation, or exerting pressure to destabilise the protein.  Lomenick et al 
developed a method named drug affinity responsive target stability (DARTS, Fig 4C)) that relies on the 
reduced susceptibility of proteins to proteolysis when a protein is bound by a drug, due to an 
increased stability of target protein upon drug binding (72).  They subjected purified immunophilin 
FKBP12 to proteolysis by the protease subtilisin in the presence/absence of several drugs including 
FKBP12 inhibitors rapamycin and FK506, and demonstrated that FKBP12 was only protected from 
proteolysis when its own inhibitors were present.  To test the method at a proteome-wide scale, they 
subjected human Jurkat cell lysates to proteolysis in the presence/absence of the EF-1α inhibitor 
didemnin, and SDS-PAGE revealed that a protein of the same mass as EF-1α was protected by the 
inhibitor.  Protein sequencing by LC-MS/MS confirmed that the band was EF-1α, demonstrating that 
DARTS can be used to identify targets of drugs in a label-free manner.  Advantages to this technique 
are that the targets of weak inhibitors are able to be identified, and whole cell lysates, as opposed to 
purified protein, can be utilized (72).  Furthermore, this technique can be used in any organism, and is 
not restricted to those in which genetic knockdown or overexpression libraries can be easily created.  
The authors describe limitations to the technique, such as the influence of binding affinity, protein 
abundance, and the susceptibility of the protein to endogenous proteolysis.  Further refinement of 
DARTS is currently aimed at identifying conditions under which lower abundance proteins can be 
identified and the optimal mass spectrometry conditions for peptide fragment identification (72). 
 
In a similar vein to DARTS, proteins interacting with ligand are less sensitive to heat-induced 
unfolding.  Thermal shift (also known as differential scanning fluorimetry) is a rapid and inexpensive 
technique which has been used to study this thermal stabilisation in a wide range of proteins under 
varying conditions or upon the binding of an interacting ligand.  In this method, the temperature at 
which a protein unfolds is measured by an increase in fluorescence caused by the binding of an 
environmentally sensitive dye (73,74) (e.g. SYPRO Orange) to exposed hydrophobic regions (Fig 4D). 
The increase in fluorescence can be monitored in a real-time PCR instrument (75) and is plotted as a 
function of temperature, generating a sigmoidal curve that can be described by a two-state transition. 
The inflection point of the transition curve is then calculated using the Boltzmann equation. The 
binding of low molecular weight ligands can increase the thermal stability of a protein (76–79) and the 
binding affinity measured from the shift in the unfolding temperature (or melting point) termed ΔTm.  
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Fig 4.  Affinity-based methods for target isolation for subsequent identification. 
    A. Affinity chromatography:  1) The drug (grey hexagon) is first modified by immobilising it to a matrix.         
2) The high affinity target (yellow shape) is captured by passing the lysate over the immobilised drug and non-
bound proteins are washed away.  Note that the low-affinity target (light yellow shape) is not captured by this 
method.  3) The high-affinity target is eluted by the addition of soluble drug. 
    B. Photo-affinity labeling:  1) The drug (grey hexagon) is functionalised to a photo-affinity probe with 
photoreactive moiety (blue line) and alkyne handle (red lines) attached via a disulfide bond.  2) The photo-affinity 
probe is trafficked to its target(s) in vivo and then covalently cross-linked to them following UV-activation of the 
photoreactive moiety.  Both high- and low-affinity targets (dark and light yellow shapes respectively) are labeled 
specifically with this technique, while highly abundant proteins (orange triangles) may be non-specifically labeled 
due to UV-activation of probe not bound to target.  3) Proteins are extracted and an azide-affinity tag (e.g., biotin-
azide, green circle) is “clicked” on.  Some non-specific binding of the tag to non-target proteins (red oval) may 
occur.  4) Biotin affinity tagged proteins are captured on streptavidin agarose (grey cups) and non-tagged proteins 
are washed away.  5) Photo-affinity labeled proteins can be eluted through cleavage of the disulfide bond with 
reducing agent (e.g., DTT).  High- and low-affinity targets will be enriched, along with highly abundant 
contaminants labeled non-specifically, while proteins bound non-specifically to the affinity tag will remain 
attached.  
    C. DARTS:  1) The unmodified drug (grey hexagon) is added to a cell lysate.  2) The presence of the drug 
stabilises the protein, making it less susceptible to proteolysis by proteases (yellow pacman).  When cut and 
uncut samples are run in a gel the targets should remain visible following SDS-PAGE and subsequent staining.  
The bands can then be cut out and target protein extracted from the gel for subsequent identification by MS. 
    D. Thermal shift:  1) The protein in its native conformation binds no SYPRO orange (yellow circles) as 
hydrophobic regions of the protein are buried.  2)  As the temperature increases, the protein unfolds due to 
thermal instability and SYPRO orange binds to hydrophobic regions as they become exposed, causing the dye to 
emit fluorescence at 610 nm (orange circles).  3) Following a peak in intensity, a gradual decline in fluorescence 
is observed as protein precipitates and aggregates, displacing bound SYPRO orange (yellow circles).  The 
binding of a drug to its purified target can stabilize the target’s secondary structure and make it less susceptible to 
heat denaturation (red versus blue lines). 
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Thermal shift can be utilised for the screening of small-molecule and ligand libraries in the drug 
discovery process. Furthermore, the assay has also been utilised to screen buffer conditions in efforts 
to maximise protein stability during purification, storage, biochemical characterization, and 
crystallography trials (80,81). Unlike many other biochemical / biophysical techniques, thermal shift 
does not require a prior knowledge of the targets’ function. Furthermore, the technique is amenable to 
high-throughput screening due to its multiwell format, low protein concentration requirement, and rapid 
protocol (82). 
 
A number of thermal shift assay variations have been described in recent years. In addition to SYPRO 
Orange, alternative dyes or probes may be utilised, allowing for the screening of proteins in the 
presence of surfactants (DCVJ (83)) or analysis of membrane proteins (CPM (84)), BFC (85)), etc. In 
Fast Parallel Proteolysis (FASTpp), the thermal melting of protein domains can be determined in cell 
lysates through the use of a thermostable protease (86). Similarly, the Cellular Thermal Shift Assay 
(CETSA) allows for thermal shift measurements in the context of cell lysates, whole cells, or tissues; 
preserving posttranslational modifications, expression levels, and the local environment of the 
endogenous protein (87). Irrespective of the specific technique or dye utilised, thermal shift may not be 
amenable for a small number of intrinsically disordered proteins. Furthermore, the assay provides 
initial evidence of ligand interactions, potentially requiring alternative, biochemical validation. Caution 
must also be taken during data analysis and compound ranking as the ΔTm value of a protein in the 
presence of a ligand may not be a true reflection of their relative affinities. 
 
Perspective 
 
The identification of drug modes of action is becoming an essential component of the drug discovery 
process. The resurgence of phenotypic screening, yielding lead compounds with unknown modes of 
action creates a bottleneck, in that further lead optimisation is often difficult while their targets remain 
unknown.  In addition, there is growing realisation that lead compounds identified through target-based 
screening do not solely interact with the target screened against, but also likely interact with several 
unknown targets, which potentially include desirable secondary targets, undesirable off-targets and 
components of drug uptake and efflux systems.  These unknown targets can often result in lead 
compound rejection later in the drug discovery process after a significant investment of time and 
money has been spent optimising a lead compound against a purified target.  However, by identifying 
the additional targets (and particularly off-targets), lead compounds can be further optimised to 
prevent their interaction and rejection from further development, thereby lowering the high attrition rate 
in drug discovery. 
  
There are now a growing number of tools that greatly aid the identification of drug modes of action.  
Several methods can be employed to isolate targets through their direct interaction with drugs for their 
subsequent identification.  Traditionally, a drug would be modified by coupling it to a matrix and targets 
identified through affinity chromatography, however, the technique is limited by the strength of 
thedrug-target interaction and weak interactions may be missed as weakly-bound proteins may wash 
too easily off the matrix.  To circumvent this limitation, a drug can be modified to include a bi-functional 
tag comprising photo-affinity and molecular handle moieties to covalently cross-link the drug to its 
targets, allowing weak interactions to be detected.  In addition, the versatility of the molecular handle 
allows the modified drug to be used in a variety of different applications.  While both affinity 
chromatography and photo-affinity labelling can be ideal for target isolation and identification, they 
both require the chemical modification of the drug, and considerable time and experimental 
experience may be required to chemically synthesise and test suitable drug analogues that retain 
biological activity.  For projects that lack this ability, or for an alternative approach, methods that 
instead show direct interaction between targets and unmodified drugs can be employed.  TICC uses 
MS in SRM mode to identify chromatographic protein fractions containing unmodified drug, but 
requires a specialised mass spectrometrist, and as with affinity chromatography, weak interactions 
may be missed.  However, DARTS and thermal shift, which take advantage of the changes in protein 
thermostability in response to drug-binding, require little specialist skill and can therefore be applied in 
any laboratory. 
  
Several methodologies exist to determine drug modes of action indirectly, by attributing changes in 
cell phenotype to drug activity.  Advances in the “omics” fields, primarily developed as of cost-
effective, high throughput methodologies for the detailed characterisation and understanding of 
disease, now allow global analyses of entire genomes, transcriptomes, proteomes and metabolomes 
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such that drug-treated cells can be compared with untreated cells at the molecular scale.  For 
example, genomics and transcriptomics can be used to detect genetic mutations that arise from 
selection through chronic drug treatment.  The genome-wide or transcriptome-wide sequencing of 
resistance mutants can reveal mutations in primary and secondary targets, as well as in drug 
trafficking systems, providing valuable insight not only into the drugs mode of uptake and action, but 
also as to how cells adapt to drug pressure to overcome the effects of the drug.  This in turn can direct 
researchers towards suitable drugs to pair with the newly identified drug to develop drug combinations 
that make resistance less likely in the field, which not only protects the newly-developed drug from 
premature obsolescence, but improves clinical outcomes, which is the main focus of drug discovery.  
Several options are available for the generation of genetic mutants, including the spontaneous 
formation of resistance mutants, or their forced creation using genome-wide RNAi, genome-wide 
overexpression, or CRISPR/Cas9 systems, where they are available and amenable to the disease of 
interest.  Transcriptomics, proteomics and metabolomics can be used to detect changes in cell 
signalling and metabolism in response to acute drug treatment, whereby transcriptomics and 
proteomics may be most suitable for drugs that affect signalling, while metabolomics may be most 
suitable for drugs that affect metabolism.  There is a large degree of overlap between the “omics” 
methodologies and it may be worthwhile applying more than one strategy to gain confidence in the 
findings and also to develop a greater understanding of how the drug of interest works.  Ultimately 
there is no ‘one-size-fits-all’ strategy and the optimal methodologies for drug mode of action study that 
are adopted by any given project may be dictated by the tools available to the laboratory, coupled with 
the methods applicable for their disease of interest and chemical properties of the drug. 
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